Osimertinib (AZD9291) in First-line Locally Advanced or Metastatic NSCLC Patients With EGFR and EGFR T790M (AZENT)
A Phase IIa Clinical Trial to Evaluate the Safety and Efficacy of Osimertinib (AZD9291) in First-line Patients With EGFR Mutation-positive Locally Advanced or Metastatic NSCLC and Concomitant EGFR T790M Mutation at Time of Diagnosis
Sponsor: AstraZeneca
This PHASE2 trial investigates Non-Small Cell Lung Cancer and is currently completed. AstraZeneca leads this study, which shows 10 recorded versions since 2016 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
10 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Feb 2025 — Sep 2025 [monthly]
Completed PHASE2
-
Sep 2024 — Feb 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2
▶ Show 5 earlier versions
-
Dec 2020 — Jan 2021 [monthly]
Completed PHASE2
-
Apr 2020 — Dec 2020 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Oct 2019 — Apr 2020 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Jun 2018 — Oct 2019 [monthly]
Recruiting PHASE2
-
Jan 2017 — Jun 2018 [monthly]
Recruiting PHASE2
First recorded
Sep 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- AstraZeneca
- MedSIR
For direct contact, visit the study record on ClinicalTrials.gov .